[{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Theradex Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"||antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Theradex Oncology","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Theradex Oncology"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"University of Iowa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ University of Iowa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ University of Iowa Pharmaceuticals"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ WestPark Capital","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ WestPark Capital"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"WestPark Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ WestPark Capital","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ WestPark Capital"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Alliance Global Partners","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Alliance Global Partners"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase II","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Boustead Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Boustead Securities","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ Boustead Securities"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"TCG GreenChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"antivirals","graph1":"Oncology","graph2":"Phase I","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ TCG GreenChem","highestDevelopmentStatusID":"6","companyTruncated":"Shuttle Pharmaceuticals \/ TCG GreenChem"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Georgetown University","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"SP-2-225","moa":"HDAC-6","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Georgetown University","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Georgetown University"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SP-1-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Shuttle Pharmaceuticals","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Shuttle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shuttle Pharmaceuticals \/ University of California","highestDevelopmentStatusID":"4","companyTruncated":"Shuttle Pharmaceuticals \/ University of California"}]
Find Clinical Drug Pipeline Developments & Deals by Shuttle Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
